Literature DB >> 21220460

Off-label use of recombinant factor VIIa: why we need better drug monitoring.

Paul C Hébert1, Dean Fergusson, Matthew B Stanbrook.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21220460      PMCID： PMC3017248          DOI： 10.1503/cmaj.101842

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  6 in total

1.  Treatment of traumatic bleeding with recombinant factor VIIa.

Authors:  G Kenet; R Walden; A Eldad; U Martinowitz
Journal:  Lancet       Date:  1999-11-27       Impact factor: 79.321

Review 2.  Use of recombinant factor VIIa for the prevention and treatment of bleeding in patients without hemophilia: a systematic review and meta-analysis.

Authors:  Yulia Lin; Simon Stanworth; Janet Birchall; Carolyn Doree; Christopher Hyde
Journal:  CMAJ       Date:  2010-11-15       Impact factor: 8.262

3.  Indication creep: physician beware.

Authors:  Paul C Hébert; Matthew Stanbrook
Journal:  CMAJ       Date:  2007-09-05       Impact factor: 8.262

4.  Safety of recombinant activated factor VII in randomized clinical trials.

Authors:  Marcel Levi; Jerrold H Levy; Henning Friis Andersen; David Truloff
Journal:  N Engl J Med       Date:  2010-11-04       Impact factor: 91.245

5.  Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.

Authors:  Haleema Shakur; Ian Roberts; Raúl Bautista; José Caballero; Tim Coats; Yashbir Dewan; Hesham El-Sayed; Tamar Gogichaishvili; Sanjay Gupta; Jorge Herrera; Beverley Hunt; Pius Iribhogbe; Mario Izurieta; Hussein Khamis; Edward Komolafe; María-Acelia Marrero; Jorge Mejía-Mantilla; Jaime Miranda; Carlos Morales; Oluwole Olaomi; Fatos Olldashi; Pablo Perel; Richard Peto; P V Ramana; R R Ravi; Surakrant Yutthakasemsunt
Journal:  Lancet       Date:  2010-06-14       Impact factor: 79.321

6.  Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis.

Authors:  Charles Natanson; Steven J Kern; Peter Lurie; Steven M Banks; Sidney M Wolfe
Journal:  JAMA       Date:  2008-04-28       Impact factor: 56.272
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.